Evidence map›Paper›PMID 29089382›Full record

ArticleGut2018

Long-term proton pump inhibitors and risk of gastric cancer development after treatment for

Ka Shing Cheung, Esther W Chan, Angel Y S Wong, Lijia Chen, Ian C K Wong, Wai Keung Leung

Open access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Gut, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 206 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
206citing papers in PubMed, 12 pooled it
46.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

206 citing papers in PubMed, 12 syntheses or guidelines pooled it, 432 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. The association between diabetes and gastric cancer: results from the Stomach Cancer Pooling Project Consortium.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2022
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Guideline
  13. Trial
  14. Trial
  15. Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT.Health technology assessment (Winchester, England) · 2021
    Trial
  16. Trial
  17. Review
  18. Article
  19. Review
  20. Article

146 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 4 countries.

Ka Shing CheungDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Esther W ChanDepartment of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, The University of Hong Kong, Hong Kong.
Angel Y S WongDepartment of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, The University of Hong Kong, Hong Kong.
Lijia ChenDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Ian C K WongDepartment of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, The University of Hong Kong, Hong Kong.
Wai Keung LeungDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Queen Mary Hospital · CNUniversity of Hong Kong · HKUniversity College Lahore · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveProton pump inhibitors (PPIs) is associated with worsening of gastric atrophy, particularly in DESIGNS: This study was based on a territory-wide health database of Hong Kong. We identified adults who had received an outpatient prescription of clarithromycin-based triple therapy between year 2003 and 2012. Patients who failed this regimen, and those diagnosed to have GC within 12 months after HP therapy, or gastric ulcer after therapy were excluded. Prescriptions of PPIs or histamine-2 receptor antagonists (H2RA) started within 6 months before GC were excluded to avoid protopathic bias. We evaluated GC risk with PPIs by Cox proportional hazards model with propensity score adjustment. H2RA was used as a negative control exposure.

resultAmong the 63 397 eligible subjects, 153 (0.24%) developed GC during a median follow-up of 7.6 years. PPIs use was associated with an increased GC risk (HR 2.44, 95% CI 1.42 to 4.20), while H2RA was not (HR 0.72, 95% CI 0.48 to 1.07). The risk increased with duration of PPIs use (HR 5.04, 95% CI 1.23 to 20.61; 6.65, 95% CI 1.62 to 27.26 and 8.34, 95% CI 2.02 to 34.41 for ≥1 year, ≥2 years and ≥3 years, respectively). The adjusted absolute risk difference for PPIs versus non-PPIs use was 4.29 excess GC (95% CI 1.25 to 9.54) per 10 000 person-years.

conclusionLong-term use of PPIs was still associated with an increased GC risk in subjects even after HP eradication therapy.

Indexed as

Helicobacter pyloriAgedAnti-Bacterial AgentsClarithromycinDatabases, FactualDrug Administration ScheduleDrug Therapy, CombinationFemaleHelicobacter InfectionsHong KongHumansIncidenceMaleMiddle AgedProton Pump InhibitorsRisk AssessmentAnti-Bacterial AgentsClarithromycinProton Pump Inhibitorsgastric adenocarcinomaHelicobacterpyloristomach cancer

Identifiers

PMID29089382
OpenAlexW2766436834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.